V Roadmap for introduction and roll-out of Janssen VAC52150 (Ad26.ZEBOV, MVA-BN®-Filo) Ebola Virus Disease vaccine in African countries PDF
V Roadmap for introduction and roll‐out of Merck rVSV‐ZEBOV Ebola Virus Disease vaccine in African countries PDF
V Terms of Reference for the Technical Advisory Group on Snake Antivenom Immunoglobulin Listing (TAG-SAIL) PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Grey Cap PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Purple Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Grey Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Orange Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Purple Cap PDF
V WHO Product Leaflet for Health Workers - Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD PDF
V WHO Recommendation for EUL of AZD1222 submitted by AstraZeneca AB and manufactured by SK Bioscience Co Ltd. (Published: 23 February 2021) PDF
V WHO Summary of Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF
V WHO workshop on implementation of good manufacturing practices for biological products, Seoul, September 2018 PDF